Nightingale Health Plc

Stock exchange release

17 March 2025 at 4:15 p.m. EET

 

The Finnish Financial Supervisory Authority today approved Nightingale Health Plc’s (“Nightingale Health” or the “Company”) Finnish-language prospectus (the “Finnish Prospectus”) in connection with the Company’s transfer from the Nasdaq First North Growth Market Finland marketplace to the Main Market of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”).

 

The Finnish Prospectus will be available on or about 17 March 2025 on Nightingale Health’s website at https://ir.nightingalehealth.com/fi/paalistasiirtyma-2025. The English-language translation of the Finnish Prospectus will be available on Nightingale Health’s website at https://ir.nightingalehealth.com/main-market-listing-2025 on or about 17 March 2025.

 

The Company filed a listing application with Nasdaq Helsinki on 12 March 2025 to list the Company’s Series B shares (the “Shares”) on the Main Market of Nasdaq Helsinki. Trading in the Shares is expected to commence on the Main Market of Nasdaq Helsinki on or about 19 March 2025, provided that Nasdaq Helsinki approves the Company’s listing application.

 

 

For further information, please contact:

 

Teemu Suna, CEO

ir@nightingalehealth.com

 

Certified Adviser

 

Oaklins Finland Ltd, tel. +358 9 6129 670

 

 

About Nightingale Health

 

Nightingale Health has developed the world’s most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

 

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. Read more: https://nightingalehealth.com/